Drug Trial Radar · NCT06190275
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
May 12, 2024
Primary completion
Apr 30, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Grit BiotechnologyIndustry
- Sponsor type
- Industry
- Collaborators
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- First posted
- Jan 5, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single-arm early exploratory clinical study. designed to evaluate the safety and tolerability of GT201 in combination with a PD-1 inhibitor for the treatment of advanced head and neck tumor subjects with safety and tolerability, as well as pharmacokinetic characterization and efficacy The study consists of two phases. The study consists of two phases, a dose-escalation phase and a dose-expansion phase.
Conditions
- HNSCC
Interventions
GT201 in combination with PD-1 inhibitorsBiological
GT201 in combination with a PD-1 inhibitor for advanced head and neck tumors
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidience and severity of adverse events per CTCAE 5.0Time frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Ninth People's Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.